KG LEGAL \ INFO
BLOG

“For Research Use Only” Is Not a Legal Shieldgg

Publication date: November 16, 2026

Online sales of semaglutide and other active substances in Poland – regulatory exposure for sellers, marketplaces, advertisers and logistics operators

Vials of semaglutide and other peptides are sold online in Poland as “research chemicals” and delivered to parcel lockers without a prescription. The label is meant to keep the product outside pharmaceutical law. It does not: under EU and Polish law the classification of a product follows its presentation and its effect, not the seller’s disclaimer. For businesses, the practical question is therefore not whether this trade is legal, but who in the chain – seller, marketplace, advertiser, influencer, payment or logistics provider – carries the criminal, administrative and civil risk, and how quickly Polish enforcement tools are catching up.

More

Ageing biomarkers as evidence of geroprotective efficacy

Publication date: November 10, 2026

Clinical research, diagnostic testing and commercialisation under Polish and EU law

Law as at 5 November 2026

Abstract

A change in an epigenetic clock may justify further investigation of a medicine. Its value as evidence of benefit depends on what the clock measures, the population in which it has been validated and whether treatment effects on the score predict effects on health. The same assay may be used to analyse archived samples, select participants for treatment or sell a test to consumers. Each use raises a different legal question. This article traces those questions from trial design through to commercial use, with particular attention to Polish law on medical experiments, performance studies, access to medical records and the use of data from non-commercial clinical trials.

Keywords  ageing biomarkers, geroprotectors, clinical trials, IVDR, biobanks, genetic data

More

Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective

Publication date: September 15, 2026

ABA ILS, Life Sciences and Healthcare Committee, September 2026Prepared by KIELTYKA GLADKOWSKI KG LEGAL

More

Biostimulants under the microscope of the law – where does information end and prohibited advertising of medical devices begin?

Publication date: July 24, 2026

Biostimulants in aesthetic medicine – current regulatory challenges for manufacturers, distributors and clinics

The aesthetic medicine market is currently one of the fastest-growing healthcare segments in Europe. Particularly dynamic growth is observed in so-called tissue biostimulants, preparations used to stimulate the body’s natural regenerative processes. While traditional fillers dominated just a few years ago, today both manufacturers and physicians are increasingly turning to preparations containing poly-L-lactic acid (PLLA), calcium hydroxyapatite, polynucleotides, and collagen preparations, whose mechanism of action is based on the stimulation of tissue regeneration processes rather than solely on mechanical effects.

More

A Major Milestone for KG Legal’s Data, AI & Cybersecurity Practice: Exclusive Poland Contribution to OneTrust DataGuidance

Publication date: July 07, 2026

We are delighted to share an important milestone in the continued development of KG Legal’s Data, AI & Cybersecurity Desk.

It has been a great honour to serve as the exclusive expert contributors for Poland to the OneTrust DataGuidance Privacy Overview – Poland, one of the world’s leading professional legal compliance resources relied upon by in-house counsel, privacy professionals, compliance officers, multinational organisations and technology companies operating across multiple jurisdictions.

More

UP